Moderna’s New Flu Shot Shows Strong Results in Older Adults
By I. Edwards HealthDay Reporter
TUESDAY, July 1, 2025 — Moderna’s new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial, the company announced Monday.
The vaccine, called mRNA-1010, was tested in a Phase 3 study in adults aged 50 and older. It worked better than a standard-dose flu vaccine, providing 26.6% more protection against the flu overall, the company said.
In adults 65 and older, the vaccine showed a 27.4% improvement.
“The severity of this past flu season underscores the need for more effective vaccines,” Moderna CEO Stéphane Bancel told The Wall Street Journal.
“An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination vaccines,” he added.
Moderna said the trial showed strong results in folks across different age groups, health conditions and even among people who had been vaccinated in for the flu in the past.
The company plans to present the full data at an upcoming medical conference and publish the results in a peer-reviewed journal.
Moderna also said it will work with health regulators on the next steps for possible approval of the vaccine, The Wall Street Journal said.
The news comes amid continuing interest in mRNA vaccine technology, even as public views shift. Moderna gained prominence during the COVID-19 pandemic but now faces more political scrutiny as the Trump administration considers new rules for vaccines.
The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still down about 32% for the year.
Sources
- The Wall Street Journal, June 30, 2025
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2025
Further Support and Information on COVID-19
Read this next
FDA Approves Prefilled Syringe Presentation for Shingles Vaccine
MONDAY, July 21, 2025 -- The U.S. Food and Drug Administration has approved a prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted) for the...
Few Babies Getting RSV Antibody Shot, Beyfortus, Study Says
THURSDAY, July 17, 2025 — A new antibody shot that protects babies against RSV infection could be struggling to gain traction, researchers report. Only about a third (35%)...
WHO, UNICEF Say More Than 14 Million Infants Worldwide Remain Unvaccinated
WEDNESDAY, July 16, 2025 -- Data released this week by the World Health Organization and UNICEF indicate modest gains in childhood vaccination rates, but globally, more than 14...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.